ACR Concerned with MedPAC’s Cutting Part B Reimbursement

Save

The American College of Rheumatology (ACR) today expressed disappointment that the Medicare Payment Advisory Commission (MedPAC) has recommended yet another cut to physician reimbursement for infusing life-altering treatments as part of its June 2023 Report to the Congress: Medicare and the Healt

Higher Genetic Loads Linked to Worse Systemic Lupus

Save

A Korean study of a large systemic lupus erythematosus (SLE) cohort shows by genomic analysis, that higher weighted genetic risk scores (wGRS) is associated with earlier SLE onset, higher anti–Sm antibody positivity, lupus nephritis and more diverse lupus manifestations.

Why Depression Screening Should be Mandatory at Each Visit

Save

Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

High Mortality Rates with Depression in Rheumatoid Arthritis

Save

A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).  

Diagnostic Yield of Cranial and Large Vessel Imaging in GCA

Save

Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA).

EULAR Offers Tips on Psoriasis Progression to PsA

Save

Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" documentopens in a new tab or window from the European Alliance of Associations for Rheumatology (EULAR).

Time to Risk Stratify Methotrexate Lab Monitoring?

Save

A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy.

Biosimilars Match Biologic Originators in Rheumatoid Arthritis

Save

A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).

EULAR 2023 recommendation for imaging in large vessel vasculitis

Save

Diagnosis of large vessel vasculitis can be challenging, and imaging modalities help with not only the diagnosis but sometimes in assessing flares in the disease. At EULAR 2023, recommendations for imaging modalities for large vessel vasculitis were discussed. These were evidence-based recommendations adapted for practicality in clinical use.  

EULAR 2023 Notes from Milan (6.09.2023)

Save

Dr. Jack Cush reviews highlight abstracts and sessions - covering lupus, RA, gout, Still's disease, safety data, AI in medicine and more - from last week's EULAR 2023 Congress held in Milan, Italy.

Combining a Tyk2 inhibitor with a JAKi in RA?

Save

At EULAR 2023, there was a late breaking abstract that compared difficult to treat patients with RA who had received treatment (including TNFi and JAKi in some patients) previously and still had active disease.

A step change towards self-empowerment for people living with SLE

Save

In my focus group consisting of people living with SLE and their carers, one of the keys issues raised by them was pertaining to poor reliable information about their condition. At the 2023 EULAR Congress in Milan, I learned about the wide scale dissemination and international launch of Lupus100.org project.